We are live on ! Find out more
CTIC

CTI BioPharma

Delisted

CTIC was delisted on the 23rd of June, 2023.

61 hedge funds and large institutions have $26.7M invested in CTI BioPharma in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.72% less ownership

Funds ownership: 28.95% → 25.23% (-3.7%)

9% less funds holding

Funds holding: 67 → 61 (-6)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

65% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 23

81% less capital inflows, than outflows

Capital inflows: $916K | Capital outflows: $4.73M

Holders
61
Holders Change
-6
Holders Change %
-8.96%
% of All Funds
1.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
23
Closed
13
Calls
$5​K
Puts
–
Net Calls
+$5​K
Net Calls Change
-⁠$11​K

CTIC Hedge Fund Activity: Q3 2016 in Review

61 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma (CTIC) for Q3 2016, worth a combined $26.7M — down 3.6% from $27.7M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CTIC and 8 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, adding an estimated $601K. The largest seller was Fidelity Investments, cutting an estimated $2.42M.

  • 61 institutional investors held CTI BioPharma (CTIC) as of Q3 2016, down from 67 in Q2 2016.
  • Funds reported $26.7M of CTI BioPharma stock for Q3 2016, down 3.6% quarter-over-quarter.
  • 8 funds opened new CTI BioPharma positions in Q3 2016 and 13 closed out, a net change of -5 holders.
  • The largest CTI BioPharma buyer in Q3 2016 was Renaissance Technologies, an estimated $601K added.
  • The largest CTI BioPharma seller in Q3 2016 was Fidelity Investments, an estimated $2.42M sold.

Based on aggregated 13F filings for Q3 2016.